Summary: Women who suffer from eating disorders from anorexia to obesity have lower levels of allopregnanolone, a progesterone metabolite previously linked to mood disorders, a new study reports.
Source: University of Illinois at Chicago.
Women at opposite extremes of the weight spectrum have low levels of the neuroactive steroid allopregnanolone, according to new research published in the journal Neuropsychopharmacology.
Previous research has linked low levels of allopregnanolone — known to scientists as “allo” — to depression and anxiety, which are common mood disorders associated with anorexia nervosa and obesity.
Allo is a metabolite of the hormone progesterone, one of the two major female hormones (the other being estrogen). Allo binds to receptors for the neurotransmitter gamma-aminobutyric acid (GABA) in the brain. These receptors are also the targets of anti-anxiety drugs such as benzodiazepines. Allo works by enhancing the signal produced when GABA binds to its receptor, generally producing a positive mood and feelings of well-being.
More than 50 percent of women with anorexia nervosa have depression or anxiety, and 43 percent of adults who are obese have depression.
Low levels of allo have been linked to depression and anxiety in numerous previous studies, including people with depression and post-traumatic stress disorder. But the chemical — and its impact on mood — has not been measured in anorexic or obese women.
“We are beginning to see more and more evidence that low allo levels are tightly linked to depression, anxiety, post-traumatic stress disorder and other mood disorders,” said Graziano Pinna, associate professor of psychiatry in the University of Illinois at Chicago College of Medicine and an author on the paper. “To see that women with anorexia nervosa and obesity have low levels adds to the picture that the role of allo is under-recognized in mood disorders.”
Pinna’s colleagues, led by Dr. Karen Miller, professor of medicine at Harvard Medical School, recruited 12 women with anorexia nervosa and amenorrhea (stopped having their menstrual periods) whose body mass indices were less than 18.5; 12 normal-weight women with BMIs between 19 and 24; and 12 obese women with BMIs at 25 or higher. None of the women had received a diagnosis of depression or ever took antidepressants. The average age of the participants was 26 years old.
Participants completed questionnaires to assess for depression and anxiety and had blood drawn. Blood measurements of allo and other hormones were performed by Pinna’s lab at the UIC. The lab had previously developed a novel, highly sensitive method technology to detect sex hormones and their metabolites. Pinna’s lab is one of only three in the United States performing these measurements, which use gas chromatography and mass spectrometry to pick up extremely small levels of these chemicals in blood serum, saliva and brain tissue.
The researchers found that in women with anorexia nervosa and in obese women, blood levels of allo were 50 percent lower than they were in women with normal BMIs, and women who were clinically obese had allo levels approximately 60 percent lower than women with normal weights.
The researchers also found that levels of allo in all participants correlated with the severity of their depression and anxiety symptoms as measured by the questionnaires. Participants with lower levels of allo had greater severity of depression symptoms.
Progesterone levels were similarly low across all groups, suggesting that the decrease in allo in participants with anorexia nervosa and obesity may have been caused by improper functioning of enzymes responsible for the metabolism of progesterone into allo.
“Women with anorexia nervosa had low progesterone because they were amenorrheic, and the other two groups also had low progesterone levels because their blood was taken in the follicular phase when progesterone is naturally low,” said Pinna. “That we found that obese women had lower allo levels than normal weight participants adds to growing evidence that this steroid is involved in depression and anxiety regardless of how much progesterone is available to begin with.”
Pinna believes that the enzymes that convert progesterone into allo may not be working properly, causing decreases in allo that lead to mood disorders. “Drugs that increase the efficacy of these enzymes may be useful in helping to boost allo levels,” he said. “But more research is needed to figure out exactly the deficit in the metabolism of progesterone into allo so that precision medicines using allo as a biomarker can be developed.”
“Depression is an incredibly prevalent problem, especially in women, and also particularly at the extremes of the weight spectrum,” said Miller. “The hope is that a greater understanding of mechanisms contributing to these disorders — including abnormalities in the regulation of hormones and their neuroactive metabolites — may lead to new targeted therapies in the future.”
Pinna is leading preclinical studies of drugs designed to boost allo levels using several pharmacological strategies. These drugs have had promising effects in mouse models of PTSD and depression.
Marianela Nelson of UIC; Dr. Laura Dichtel, Dr. Elizabeth Lawson, Dr. Melanie Schorr, Erinne Meenaghan, Margaret Paskal, Kamryn Eddy, Dr. Anne Kilbanski, and Dr. Karen Miller of Harvard Medical School and Massachusetts General Hospital; and Dr. Ann Rasmusson of Boston University School of Medicine, are co-authors on the paper.
Funding: is work was supported by grants T32 DK007028, K24 HL092902, R01 MH083657 and R01 DK05262 from the National Institutes of Health and with support from Harvard Catalyst, the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award UL1 TR001102); National Center for PTSD, Department of Veteran Affairs, and Harvard University and its affiliated academic health care centers.
Source: Sharon Parmet – University of Illinois at Chicago Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is in the public domain. Original Research:Abstract for “Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum” by Laura E Dichtel, Elizabeth A Lawson, Melanie Schorr, Erinne Meenaghan, Margaret Lederfine Paskal, Kamryn T Eddy, Graziano Pinna, Marianela Nelson, Ann M Rasmusson, Anne Klibanski & Karen K Miller in Neuropsychopharmacology. Published online November 1 2017 doi:not available
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]University of Illinois at Chicago “Both Obese and Anorexic Women Have Low Levels of ‘Feel Good’ Neurosteroid.” NeuroscienceNews. NeuroscienceNews, 10 November 2017. <https://neurosciencenews.com/allo-anorexia-obesity7919/>.[/cbtab][cbtab title=”APA”]University of Illinois at Chicago (2017, November 10). Both Obese and Anorexic Women Have Low Levels of ‘Feel Good’ Neurosteroid. NeuroscienceNews. Retrieved November 10, 2017 from https://neurosciencenews.com/allo-anorexia-obesity7919/[/cbtab][cbtab title=”Chicago”]University of Illinois at Chicago “Both Obese and Anorexic Women Have Low Levels of ‘Feel Good’ Neurosteroid.” https://neurosciencenews.com/allo-anorexia-obesity7919/ (accessed November 10, 2017).[/cbtab][/cbtabs]
Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum
3α-5α-Tetrahydroprogesterone, a progesterone metabolite also known as allopregnanolone, and 5α-androstane-3α,17β-diol, a testosterone metabolite also known as 3α-androstanediol, are neuroactive steroids and positive GABAA receptor allosteric modulators. Both anorexia nervosa (AN) and obesity are complicated by affective co-morbidities and hypothalamic-pituitary-gonadal dysregulation. However, it is not known whether neuroactive steroid levels are abnormal at the extremes of the weight spectrum. We hypothesized that serum allopregnanolone and 3α-androstanediol levels would be decreased in AN compared to healthy controls (HC) and negatively associated with affective symptoms throughout the weight spectrum, independent of body mass index (BMI). Thirty-six women were 1 : 1 age-matched across three groups: AN, HC, and overweight/obese (OW/OB). AN were amenorrheic; HC and OW/OB were studied in the follicular phase. Fasting serum neuroactive steroids were measured by gas chromatography/mass spectrometry. Mean Hamilton depression and anxiety scores were highest in AN (p<0.0001). Mean serum allopregnanolone was lower in AN and OW/OB than HC (AN 95.3±56.4 vs OW/OB 73.8±31.3 vs HC 199.5±167.8 pg/ml, p=0.01), despite comparable mean serum progesterone. Allopregnanolone, but not progesterone, was negatively associated with depression and anxiety symptom severity, independent of BMI. Serum 3α-androstanediol levels did not differ among groups and were not associated with depression or anxiety scores, despite a significant negative association between free testosterone levels and both anxiety and depression severity. In conclusion, women at both extremes of the weight spectrum have low mean serum allopregnanolone, which is associated with increased depression and anxiety severity, independent of BMI. Neuroactive steroids such as allopregnanolone may be potential therapeutic targets for depression and anxiety in traditionally treatment-resistant groups including AN.
“Neuroactive Steroids and Affective Symptoms in Women Across the Weight Spectrum” by Laura E Dichtel, Elizabeth A Lawson, Melanie Schorr, Erinne Meenaghan, Margaret Lederfine Paskal, Kamryn T Eddy, Graziano Pinna, Marianela Nelson, Ann M Rasmusson, Anne Klibanski & Karen K Miller in Neuropsychopharmacology. Published online November 1 2017 doi:not available